Yasrebi H.,SV Life Sciences |
Yasrebi H.,Swiss Institute of Bioinformatics
Bioinformatics | Year: 2011
Summary: SurvJamda (Survival prediction by joint analysis of microarray data) is an R package that utilizes joint analysis of microarray gene expression data to predict patients' survival and risk assessment. Joint analysis can be performed by merging datasets or meta-analysis to increase the sample size and to improve survival prognosis. The prognosis performance derived from the combined datasets can be assessed to determine which feature selection approach, joint analysis method and bias estimation provide the most robust prognosis for a given set of datasets. © The Author 2011. Published by Oxford University Press. All rights reserved. Source
News Article | August 26, 2015
Venture firm Formation 8 has surpassed its $100 million target for its new hardware fund, and it is eyeing a final close with an undisclosed amount of capital, Yuliya Chernova reports for Dow Jones VentureWire. Formation 8 is among other accelerators and firms that have raised funds, including Lemnos Labs, Bolt, Root Ventures and Playground Global LLC from Android creator Andy Rubin. Formation Partner Lior Susan saidthat startups are increasingly centering their business models not on the hardware but on the data collected by the hardware and on selling the resulting analysis in software form. Soon enough, Mr. Susan said, companies will give hardware away free. Hardware attracted a record amount of venture dollars last year, with $2.76 billion invested, according to data from industry tracker Dow Jones VentureSource. The total for the first half of 2015 was $1.01 billion. Intercom Inc., an enterprise communications company, has raised $35 million in a round led by Iconiq Capital. Other investors in the Series C round include Bessemer Venture Partners and The Social+Capital Partnership. DynoSense Corp., the maker of a health scanner that the company says can measure 33 health metrics in under a minute, has raised a $9.4 million Series A round. The funding was provided by WI Harper Group, JKOM Cloud Health Technology Co., Plug and Play Tech Center, Jinmao Capital, and Wilson, Sonsini, Goodrich and Rosati. Velostrata, a startup developing technology for hybrid cloud solutions, has raised a $14 million Series A round from Norwest Venture Partners and 83North Venture Capital, which was previously known as Greylock IL. ReShape Medical Inc., which recently got regulatory clearance to sell its nonsurgical device for weight loss, has raised a $38 million Series D round to commercialize its technology. The round was led by HealthCor Partners Management, joined by Endeavour Vision SA and existing investors SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors. CargoSense Inc. has attracted $3.7 million in funding for its logistics software platform. Investors in the seed series preferred round included the Virginia Center for Innovation Technology, New Dominion Angels, Middleburg Capital Development, IrishAngels and individual angels. ELSEWHERE AROUND THE WEB: Google Ventures Funds Swedish VR Gaming Startup. Resolution Games has raised $6 million from Google Inc.’s Google Ventures and other investors to develop virtual-reality games.The cash inflow values the small game studio at roughly $25 million, a person familiar with the matter said. Hardware Startup Augury Nails $7 Million Series A Round. The startup Augury Inc., which says it has figured out a way to troubleshoot machine problems early by listening to the sounds they emit, has raised $7 million in Series A funding, The Wall Street Journal’s Yuliya Chernova reports. Formation 8 led the round using its new hardware-focused fund. Pritzker Group, a family office that has large real estate holdings, is also investing, as well as returning backers First Round Capital and Lerer Hippeau Ventures. Snapchat Names Former Mattel Executive Drew Vollero Its Finance Chief. A former former finance executive at toy maker Mattel Inc. is joining Snapchat Inc., one of the most highly valued private tech startups, to run its finances, the WSJ’s Douglas MacMillan reports. Drew Vollero is joining Spanchat as its vice president of finance and acting chief financial officer. Prenav Seeded for Robot-Guided Drones. Drone startup PreNav has raised $1.2 million for a system that can automatically fly a an unmanned aerial vehicle within centimeters of a structure, allowing for close inspection of it by people who aren’t expert pilots, the WSJ’s Lora Kolodny reports. Investors in PreNav’s seed deal included Pejman Mar Ventures, Drone.vc, Oculus VR co-founder Michael Antonov and Toivo Annus. Airbnb to Start Collecting Tourism Taxes in Paris. Home-sharing company Airbnb Inc. announced that it will begin collecting tourist taxes in Paris as of Oct. 1, the WSJ’s Sam Schichner reports. Paris will be the ninth city in which the company collects hotel taxes. Medtronic to Buy Privately Held Twelve Inc. Medtronic PLC said it has agreed to acquire Twelve Inc. for $458 million, the WSJ’s Ezequiel Minaya reports. Twelve is developing a transcatheter mitral valve replacement device. The startup–backed by investors that include Domain Associates, The Foundry, Morgenthaler Ventures, Split Rock Partners and Versant Ventures–will join Medtronic’s coronary and structural heart division within the cardiac and vascular group. Write to Mike Billings at firstname.lastname@example.org. Follow him on Twitter at @mbillings
News Article | May 20, 2015
SANTA ROSA, Calif. & PARIS--(BUSINESS WIRE)--Direct Flow Medical®, Inc., an innovative structural heart company, today announced 30-day outcomes from the DISCOVER post-market registry that demonstrate excellent real world results for the Direct Flow Medical Transcatheter Aortic Valve System consistent with the ground-breaking results seen in the DISCOVER CE Mark Trial. The data were presented yesterday at the EuroPCR conference in Paris, France by Christoph C. K. Naber, MD, PHD, from the Contilia Heart Center in Essen, Germany. The 30-day data on 250 all-comer patients from the DISCOVER post-market study showed a 98 percent survival rate, which emulated the 99 percent survival rate previously reported at 30 days from the DISCOVER CE Mark Trial. The average age of patients in the trial was 82.5 years, with a mean logistic euroSCORE of 18.3 percent. Mild or less post-procedural aortic regurgitation was achieved in 97 percent of patients, with 80 percent of patients experiencing none to trace aortic regurgitation. The stroke rate and incidence of myocardial infarction within 30 days was low, at two percent and .8 percent, respectively. A low major vascular complications rate of four percent demonstrates the system’s flexibility and trackability even in tortuous anatomy. No patient required rapid pacing during deployment or post-dilatation following deployment, minimizing the risk of hemodynamic stress. In addition, no patient required more than one valve, eliminating the need for a valve-in-valve procedure and the associated negative outcomes observed with non-retrievable transcatheter aortic valves. "Treating patients with the Direct Flow Medical valve in a real-world setting and getting the same consistent results seen in the clinical trial shows outstanding performance," said Dr. Naber. "In daily practice we are faced with patients that are normally excluded by protocol from clinical studies, but these patients need treatment, as well. It is reassuring to know that we can reproduce the same results in challenging clinical scenarios with this valve." The DISCOVER Post-Market Study is a prospective, multicenter, all-comers registry of up to 1,000 patients conducted at up to 75 European sites to evaluate the outcomes of the Direct Flow Medical valve on patients with severe aortic stenosis in routine clinical practice. The fully repositionable and retrievable Direct Flow Medical system is designed to treat patients with severe aortic stenosis, while reducing the risk of post-procedural AR, a strong predictor of long-term mortality. The system addresses this clinical concern by sealing the annulus and enabling complete assessment of hemodynamic performance with unlimited “in situ” repositioning of the valve after full deployment. The system includes a distinctive heart valve with a metal-free frame, delivered transfemorally via the same flexible delivery system for all sizes (23mm, 25mm, 27mm and 29mm). The Direct Flow Medical system received the CE Mark in January 2013 for the treatment of patients with aortic stenosis who are at extreme surgical risk. The system is currently available commercially in Europe and enrolling a pivotal trial in the United States. Founded in 2004, Direct Flow Medical, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing patient complications. The company is headquartered in Santa Rosa, California, with technology and manufacturing facilities in Lake Forest, California. The company’s proprietary technology, initially aimed at aortic valve disease, is applicable to a broad range of structural heart diseases. Direct Flow Medical investors include EDF Ventures, New Leaf Venture Partners, Spray Venture Partners, Foundation Medical Partners, VantagePoint Venture Partners, ePlanet Venture Partners, SV Life Sciences and strategic corporate investors. For further information, please visit the Web site at www.directflowmedical.com. The Direct Flow Medical Transcatheter Aortic Valve System has not been approved for use in the USA, Canada, or Japan. Direct Flow Medical and the Direct Flow logo are trademarks of Direct Flow Medical, Inc.
News Article | April 10, 2015
A strategic device company, a former Medtronic ($MDT) president and an award-winning Stanford doctor are among the financiers of Silicon Valley's EBR Systems' attempt to commercialize the first leadless pacemaker implanted in the heart's left ventricle. Along with VCs like Split Rock Partners and SV Life Sciences, the group contributed $20 million toward the groundbreaking effort. The financing will go toward clinical trials to obtain a CE mark as well as an Investigational Device Exemption permission from the FDA to test its device in the U.S. Pacemaker (also known as CRT-D) leads--or wires for stimulating the heart--have been implicated in patient safety scares. In 2012 St. Jude Medical ($STJ) yanked its QuickFlex and QuickSite pacemaker leads from the market after a few broke through their outer insulation. The problem was similar to that experienced by the company's Riata implantable defibrillator leads. Those leads have been implicated in at least two patient deaths, and the company recently agreed to pay as much as $14.25 million to settle about 950 claims related to the component. Another advantage of leadless devices is that they are easier to install in the body, resulting in a fewer complications during surgery. Meanwhile, EBR says its leadless pacemaker would improve efficacy as well. The investigational device is supposed to be implanted inside the heart's left ventricle, allowing so-called endocardial stimulation, while traditional pacemakers perform epicardial stimulation because the leads touch only the surface of the heart. About 30% of patients do not respond to their conventional pacemaker, EBR says. "Wireless pacing enables stimulation of any site inside the heart. That degree of precision and flexibility is a huge advantage over lead-based systems requiring wires. Numerous studies make it clear that the decades-old approach of wired leads has many limitations," said Stanford medical professor Dr. Thomas Fogarty in a statement. He's a recipient of the Presidential National Medal of Technology. "This technology also has huge potential implications for bradycardia, which is an abnormally slow heart rate. We can finally stimulate the left ventricle--which is the best location--instead of settling for the right ventricle. All the data we've seen indicates this can be a significant advance in treatment," Fogarty continued. Another financier in the funding round is Stephen Mahle, former president of Medtronic's Cardiac Rhythm Management division. Leerink Swann equity analysts Danielle Antalffy and Puneet Souda estimate that leadless pacemakers will earn $700 million in 2016. A dual chambered leadless pacemaker that works on both side of the heart has the potential to get the vast majority of the $3.5 billion pacemaker market, they say. St. Jude Medical claims to be working on such a device. The company's leadless Nanostim is CE-marked in Europe, and Medtronic's Micra is believed to be nearing approval on the continent as well. Both are implanted in the right ventricle. Boston Scientific's ($BSX) fast-selling S-ICD has shown the potential of cardiology products that eliminate or lessen the use of leads, albeit in the related but distinct market for implantable defibrillators. Meanwhile, the Nanostim has gotten off to a slow start in Europe after it was associated with a few patient deaths soon after it received a CE mark in 2013. Related Articles: St. Jude settles 70 suits related to Riata defibrillator leads for $14.25 million Analysts bullish on leadless pacing market, call it a $700M opportunity St. Jude Medical will test its leadless pacemaker in a massive EU postmarketing trial Medtronic follows St. Jude Medical with leadless pacemaker U.S. trial milestone St. Jude Medical grabs Nanostim for $123.5M, gaining CE marked leadless pacer Tough luck, St. Jude: No retraction for you
News Article | June 25, 2015
Catabasis Pharmaceuticals has done some strategic tinkering over the past few years, and the Cambridge, MA-based company did a bit more maneuvering on Wednesday to price its IPO. Catabasis is set to debut on the Nasdaq this morning after raising $60 million in an IPO. It had to sell more shares at a lower price than planned to get there, however: Catabasis sold 5 million shares at $12 apiece, coming in just short of the 4.3 million at $13 to $15 apiece it had projected. Shares will begin trading today under the ticker symbol “CATB.” The cash is going towards some early stage trials Catabasis is running for experimental drugs for Duchenne Muscular Dystrophy and high cholesterol levels, respectively. Catabasis just started the first of those trials—a Phase 1/2 study of a prospective Duchenne treatment called CAT-1004—last week. Catabasis was formed in 2008 and built around a technology called “SMART-Linker” used to attach two compounds together. That resulting combination forms a new chemical entity meant to hit two targets in a disease pathway at once. Its most advanced drug prospect, for instance, CAT-2003, is a chemically linked combination of niacin and the omega 3 fatty acid eicosapentaeonic acid, or EHA; CAT-1004, links a different fatty acid, docosahexaeonic acid (DHA), to salicylate. While CAT-2003 is further along than CAT-1004 in clinical trials (see below for more), Catabasis has clearly prioritized the Duchenne program first—part of a strategic shuffling the company has done to find the best path forward for its technology. CAT-1004, for instance, was first thought to be a potential treatment for type 2 diabetes and later inflammatory bowel disease before its potential for Duchenne came to the fore—it’s meant to tamp down the inflammation associated with the crippling, muscle-wasting disorder and regenerate muscle tissue. Then there’s a newer drug called CAT-2054, a next-gen version of CAT-2003. Catabasis has said that though CAT-2003 has completed three Phase 2a studies for high cholesterol, and that data “support the utility” of the drug’s technology, it’ll only move the drug forward for other serious diseases—like liver cancer—and only with the help of a partner. CAT-2054, meanwhile, began early-stage testing for patients with high cholesterol who don’t respond to other treatments, in January. Initial data from that study were released in early June; full results are expected in the third quarter. (Catabasis used a different chemical linker for CAT-2054; it’s distributed through the body differently than its predecessor, according to the IPO prospectus) With a 25.8 percent stake, SV Life Sciences is Catabasis’s largest shareholder. Others include Clarus Lifesciences II (24.9 percent), MedImmune Ventures (14.8 percent), Advanced Technology Ventures VIII (10.3 percent), and Lightstone Ventures (6.8 percent). The company has raised about $93 million in venture cash and $10 million in debt since it started up seven years ago. Citigroup, Cowen and Co., Wedbush, and Oppenheimer & Co. are underwriting the IPO.